home

LATEST ONCOPRESCRIBE UPDATES

• PIQRAY® Effective after Progression on CDK Inhibition in Advanced Breast Cancer

• Overall Survival Benefit with Frontline OPDIVO® plus YERVOY® and Limited Chemotherapy in NSCLC

• Late Breaking Abstract – ASCO 2020: Local Therapy Does Not Extend Survival in Newly Diagnosed Metastatic Breast Cancer

• Late Breaking Abstract – ASCO 2020: FDA Approves BAVENCIO® for Maintenance Treatment in Advanced Urothelial Carcinoma

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• BRAFTOVI® and ERBITUX® - for Colon Cancer

• PARAPLATIN® and VEPESID® with IMFINZI® - for Small Cell Lung Cancer

• IMFINZI® Maintenance - Small Cell Lung Cancer

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• IDHIFA® - for Acute Myeloid Leukemia

Curbside Consultation

OncoPrescribe

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management
  

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors
  

SHOW MORE